CapsoVision (CV) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CapsoVision (CV) has outperformed Stereotaxis (STXS) over the past year, gaining 38.9% versus a loss of 64.5%. CapsoVision is the larger company by market cap ($352.3 million vs $111.2 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | STXS |
|---|---|---|
| Share price | $6.62 | $1.11 |
| Market cap | $352.25M | $111.22M |
| 1-day change | +1.22% | -1.77% |
| YTD return | -38.82% | -50.87% |
| 1-year return | +38.85% | -64.47% |
| 5-year return | — | -80.94% |
| EPS (TTM) | $-0.45 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.37 | $3.59 |
| 52-week low | $4.38 | $1.09 |
| Distance from 52-week high | -56.93% | -69.08% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +43.50% | — |
| Average volume | 158.10K | 809.88K |
| Shares outstanding | 53.21M | 100.20M |
| Employees | 99 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CapsoVision is about 3.2 times larger than Stereotaxis by market value ($352.25M vs $111.22M).
- CV has outperformed STXS by 103.3 percentage points over the past year.
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
CV vs STXS FAQ
Which is bigger, CapsoVision or Stereotaxis?
CapsoVision (CV) is larger, with a market capitalization of $352.25M compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, CV or STXS?
CV returned +38.85% over the past 12 months, compared with -64.47% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.